DUBLIN , May 6, 2022 /PRNewswire/ -- The "Global Blood Collection Devices Market Size, Share & Industry Trends Analysis Report By End User, By Product, By Tubes Type, By Plasma/whole-blood Tubes Type, By Tubes System Type, By Method, By Application, By Regional Outlook and Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.
The Global Blood Collection Devices Market size is expected to reach $8 billion by 2027, rising at a market growth of 6.2% CAGR during the forecast period. Blood processing and collection are two significant steps to be performed in preanalytical laboratory testing. Legitimate blood collection and on-time processing by skilled staff utilizing efficient devices are required in order to assure test reliability. Blood collection devices have been considered inert specimen carriers. That is why laboratories are investing a bit of effort to access innovative blood collection devices with the help of which they are not required to monitor the device performance continuously. Additionally, blood is collected with the help of blood donation processes such as WB (whole blood), and after that, various components can easily be separated from it by the process of apheresis. The quantity of blood drawn depends upon the person and ought not to be more than 1% of the donor's weight. The collection can be done manually or automatically by the use of automated equipment that can even collect particular components of blood. Various advanced devices are being introduced in the market such as hematology analyzers. There are computerized and highly specialized machines which count the number of blood platelets, red & white blood cells, hematocrit level & hemoglobin present in the blood sample. With the help of a needle, phlebotomist is expected to rupture a vein and collect the blood into a glass tube which contains ETDA as additives to prevent blood coagulation. In the past few years, some diseases such as coronavirus have put human health into a threat all over the world. Diagnostics is the foremost step to be taken for the treatment of infectious diseases. It is an important step to identify efficient diagnostic strategies urgently to provide better treatment. Furthermore, effective diagnostic techniques are also important for the identification & better treatment of diseases. COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic is an unexpected public health challenge for the whole world. The pandemic is anticipated to have a substantial impact on the blood circulation device market. Independent laboratories as well as hospitals were confused in deciding either to recommend to consult with laboratory hematologists for tests that involve higher risk or not offer tests that couldn't be performed securely. This has impacted the market adversely in the initial months of the pandemic resulting in a decline in the use of blood collection devices. Whereas, rising alert and the increasing testing volumes, coupled with the requirement for regular body & health checkups will result in the growth of blood collection devices. Results presently take around four to six days for the normal population, significantly longer than two to three days required before. This is due to the prioritization of tests for symptomatic healthcare workers & hospital patients that on average take one day which is resulting in the delayed cycle. Market Growth Factors:
Technological advancements in blood collection procedures and products
Collection of blood samples of patients from difficult venous access (DVA) is not easy and even is impossible sometimes. The traditional products used for blood collection products are sometimes unable to collect blood samples efficiently. This may lead to repeated attempts for collecting blood. Also, this increases the risk of anemia & the transfer of blood-borne pathogens to phlebotomists. In order to get over this issue, innovative hematology tube designs have been launched that support capillary blood collection along with reducing the risk of processing & collection errors in patients with DVA. Rising prevalence of inherited blood disorders
If there is an issue with the blood, it may affect the total health of the body. Some types of blood disorders are platelet disorders, bleeding problems & excessive clotting that may affect the blood clots; anemia that happens when blood do not let the oxygen go through the rest of your body, blood cancers like myeloma & leukemia and eosinophilic disorders that is an issue with the particular type of white blood cells. As per the information provided by World Health Organization, hemoglobin disorders were mainly found in 60% of 229 countries and were affecting 75% of births. This encourages policymakers to find the most efficient treatment strategies. Hemophilia A affects 1 in every 5000 male births in the United States . Every year approximately 400 babies are born with hemophilia. Market Restraining Factors
High cost of automated blood collection devices
The cost involved in initial investment for the adoption of automated blood collection by the use of apheresis devices involves high costs as compared to blood collection. Also, the cost of therapeutic apheresis is high as it further involves the cost of disposables. The higher cost of these devices is leading to the lower adoption of automated blood collection devices. As many of the smaller blood banks, hospitals cannot afford to use these blood collection devices. In addition, the cost of apheresis therapy is a matter of concern for the whole world. The cost for individual apheresis treatments may widely differ.
Key Topics Covered: Chapter 1. Market Scope & Methodology Chapter 2. Market Overview 2.1 Introduction 2.1.1 Overview 2.1.1.1 Market Composition and Scenario 2.2 Key Factors Impacting the Market 2.2.1 Market Drivers 2.2.2 Market Restraints Chapter 3. Competition Analysis - Global 3.1 KBV Cardinal Matrix 3.2 Recent Industry Wide Strategic Developments 3.2.1 Partnerships, Collaborations and Agreements 3.2.2 Product Launches and Product Expansions 3.2.3 Acquisition and Mergers 3.2.4 Geographical Expansions 3.3 Top Winning Strategies 3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021) Chapter 4. Global Blood Collection Devices Market by End User 4.1 Global Hospitals, Ambulatory Surgical Centers, & Nursing Homes Market by Region 4.2 Global Diagnostic & Pathology Laboratories Market by Region 4.3 Global Blood Banks Market by Region 4.4 Global Others Market by Region Chapter 5. Global Blood Collection Devices Market by Product 5.1 Global Blood Collection Tubes Market by Region 5.2 Global Blood Collection Tubes Market by Type 5.2.1 Global Plasma/whole-blood Tubes Market by Region 5.2.2 Global Plasma/whole-blood Tubes Market by Type 5.2.2.1 Global EDTA Tubes Market by Region 5.2.2.2 Global Heparin Tubes Market by Region 5.2.2.3 Global Coagulation Tubes Market by Region 5.2.2.4 Global Glucose Tubes Market by Region 5.2.2.5 Global Others Market by Region 5.2.3 Global Serum Tubes Market by Region 5.3 Global Blood Collection Tubes Market by System Type 5.3.1 Global Vacuum Tubes Market by Region 5.3.2 Global Non-Vacuum Tubes Market by Region 5.4 Global Needles & Syringes Market by Region 5.5 Global Blood Bags Market by Region 5.6 Global Blood Collection Systems/Monitors Market by Region 5.7 Global Lancets Market by Region Chapter 6. Global Blood Collection Devices Market by Method 6.1 Global Manual Blood Collection Market by Region 6.2 Global Automatic Blood Collection Market by Region Chapter 7. Global Blood Collection Devices Market by Application 7.1 Global Diagnostics Market by Region 7.2 Global Therapeutics Market by Region Chapter 8. Global Blood Collection Devices Market by Region Chapter 9. Company Profiles 9.1 Sarstedt AG & Company 9.1.1 Company Overview 9.1.2 Recent strategies and developments: 9.1.2.1 Acquisition and Mergers 9.2 ICU Medical, Inc. 9.2.1 Company Overview 9.2.2 Financial Analysis 9.2.3 Regional Analysis 9.2.4 Research & Development Expenses 9.3 Grifols, S.A 9.3.1 Company Overview 9.3.2 Financial Analysis 9.3.3 Regional & Segmental Analysis 9.3.4 Research & Development Expenses 9.4 Retractable Technologies, Inc. 9.4.1 Company Overview 9.4.2 Financial Analysis 9.4.3 Segmental Analysis 9.4.4 Research & Development Expenses 9.5 Quest Diagnostics Incorporated 9.5.1 Company Overview 9.5.2 Financial Analysis 9.5.3 Segmental Analysis 9.5.4 Recent strategies and developments: 9.5.4.1 Partnerships, Collaborations, and Agreements: 9.5.4.2 Product Launches and Product Expansions: 9.6 Becton, Dickinson and Company 9.6.1 Company Overview 9.6.2 Financial Analysis 9.6.3 Segmental and Regional Analysis 9.6.4 Research & Development Expense 9.6.5 Recent strategies and developments: 9.6.5.1 Partnerships, Collaborations, and Agreements: 9.7 Haemonetics Corporation 9.7.1 Company Overview 9.7.2 Financial Analysis 9.7.3 Regional & Segmental Analysis 9.7.4 Research & Development Expenses 9.8 Terumo Corporation 9.8.1 Company Overview 9.8.2 Financial Analysis 9.8.3 Segmental Analysis 9.8.4 Recent strategies and developments: 9.8.4.1 Partnerships, Collaborations, and Agreements: 9.8.4.2 Product Launches and Product Expansions: 9.8.4.3 Geographical Expansions: 9.9 Fresenius SE & Co. KGaA 9.9.1 Company Overview 9.9.2 Financial Analysis 9.9.3 Segmental and Regional Analysis 9.9.4 Research & Development Expenses 9.10. Cardinal Health, Inc. 9.10.1 Company Overview 9.10.2 Financial Analysis 9.10.3 Segmental and Regional Analysis
For more information about this report visit https://www.researchandmarkets.com/r/jlw0nu
Research and Markets Laura Wood , Senior Manager press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/insights-on-the-blood-collection-devices-global-market-to-2027---featuring-icu-medical-grifols-and-quest-diagnostics-among-others-301541584.html
As we move toward the end of Q2, it’s time to start thinking about earnings. Looking back at the quarter, analysts are predicting earnings growth of 8%, which may rise to 11% heading into next year. It’s a rosy picture, but it’s also not a sure thing. GDP contracted in Q1, by nearly 1.5%, and some estimates are showing 0% growth in Q2. Such results would meet the technical definition of a recession – and recession is hardly the usual environment to find robust earnings growth. Looking at current
Companies could be returning trillions to shareholders. Here’s how to accept it.
Recessions seems to be the talk of the town these days. So: if "everyone" knows a recession is coming, does that change what the downturn looks like?
When you need another stream of income for retirement, you might consider an annuity. You purchase the annuity from an insurance company and receive payments back at a later date. Before buying an annuity, it's important to consider how much … Continue reading → The post How Much Does a $300,000 Annuity Pay Per Month? appeared first on SmartAsset Blog.
In March, Tesla (NASDAQ: TSLA) revealed its intentions to pursue a stock split, and now we have more details. A company's path to a stock split can be a bit confusing. Here's what you as a retail investor need to know about Tesla's plan.
At current levels, investors need a 7% to 8% return just to preserve their wealth.
Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.
These rapidly growing companies are begging to be bought following a peak decline of 34% for the Nasdaq.
Russia’s fiddling with gas flows to Europe could create an economic spillover effect, warns Germany’s top economy minister.
The wireless companies are boosting monthly fees and increasing the cost of mostly older cellphone plans.
Many popular companies have announced stock splits in 2022. With that in mind, we asked a panel of Motley Fool contributors to share their top picks from the list of upcoming stock splits. Nicholas Rossolillo (Fortinet): In the years leading up to and during the beginning of the pandemic, there was much talk about how cybersecurity needs have changed.
(Bloomberg) -- In 1991, Nobel laureate William Sharpe dropped a bombshell on the finance world with a paper arguing the “average” active manager will always lose out to passive strategies after fees. Most Read from BloombergProtest Latest: Tear Gas Used in Arizona; Driver Hits ProtestersSupreme Court Overturns Roe, Transforming Abortion-Rights FightJustice Kavanaugh Says States May Not Bar Travel to Obtain an AbortionGermany Pushes for G-7 Reversal on Fossil Fuels in Climate BlowEnding Roe Is In
Dividend stocks are the new darlings in S&P 500. But investors are getting burned on those stocks, too.
Tesla plant near Shanghai is going to shut down temporarily, according to reports. On Wednesday, Reuters reported that Tesla (ticker: TSLA) will shut down production in China for a couple of weeks at the start of July to upgrade equipment. Tesla didn’t return a request for comment.
A Woman's World reacts to Roe v. Wade overturned
Things aren't funny right now, but this sure is.View Entire Post ›
One of Warren Buffett's famous sayings is, "Be greedy when others are fearful." With the vast amount of selling in the past few weeks, Buffett is likely scooping up shares of his favorite companies at lower valuations. After all, Berkshire Hathaway has more than $106 billion in cash sitting on its balance sheet, just waiting to be put to good use.
The first half of 2022 is all but over, and it's been a lousy one for the stock market. The Nasdaq Composite index is down 29.3% year to date. Take Advanced Micro Devices (NASDAQ: AMD); it's down 42.7% so far this year.
A bill is headed for consideration by the full Senate that would move the age at which you have to start drawing down your retirement plan savings to 75. The House of Representatives passed a similar measure, so sponsors are … Continue reading → The post You're One Step Closer to Being Able to Delay Your RMDs in Retirement appeared first on SmartAsset Blog.
Entrepreneur, investor and philanthropist Mark Cuban began building his fortune in 1990 with the sale of his technology startup, MicroSolutions.Three decades later, his business ventures and stakes in...